Literature DB >> 11350073

Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction.

T J Bivalacqua1, W J Hellstrom, P J Kadowitz, H C Champion.   

Abstract

Nitric oxide (NO) is the principal mediator of penile erection. NO is synthesized by nitric oxide synthase (NOS). It has been well documented that the major causative factor contributing to erectile dysfunction in diabetic patients is the reduction in the amount of NO synthesis in the corpora cavernosa of the penis resulting in alterations of normal penile homeostasis. Arginase is an enzyme that shares a common substrate with NOS, thus arginase may downregulate NO production by competing with NOS for this substrate, l-arginine. The purpose of the present study was to compare arginase gene expression, protein levels, and enzyme activity in diabetic human cavernosal tissue. When compared to normal human cavernosal tissue, diabetic corpus cavernosum from humans with erectile dysfunction had higher levels of arginase II protein, gene expression, and enzyme activity. In contrast, gene expression and protein levels of arginase I were not significantly different in diabetic cavernosal tissue when compared to control tissue. The reduced ability of diabetic tissue to convert l-arginine to l-citrulline via nitric oxide synthase was reversed by the selective inhibition of arginase by 2(S)-amino-6-boronohexanoic acid (ABH). These data suggest that the increased expression of arginase II in diabetic cavernosal tissue may contribute to the erectile dysfunction associated with this common disease process and may play a role in other manifestations of diabetic disease in which nitric oxide production is decreased. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350073     DOI: 10.1006/bbrc.2001.4874

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  60 in total

Review 1.  Endothelial arginase: a new target in atherosclerosis.

Authors:  Zhihong Yang; Xiu-Fen Ming
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 2.  Arginase: a critical regulator of nitric oxide synthesis and vascular function.

Authors:  William Durante; Fruzsina K Johnson; Robert A Johnson
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

3.  Crystal structure of human arginase I complexed with thiosemicarbazide reveals an unusual thiocarbonyl mu-sulfide ligand in the binuclear manganese cluster.

Authors:  Luigi Di Costanzo; Michael E Pique; David W Christianson
Journal:  J Am Chem Soc       Date:  2007-05-01       Impact factor: 15.419

Review 4.  Arginase and vascular aging.

Authors:  Lakshmi Santhanam; David W Christianson; Daniel Nyhan; Dan E Berkowitz
Journal:  J Appl Physiol (1985)       Date:  2008-08-21

5.  Serum Arginase II level can be a novel indicator for erectile dysfunction in patients with vasculogenic erectile dysfunction: a comparative study.

Authors:  Abdel Shakour Abdel Hafez Abdel Wahed; Mohamed Abdel Mawgood Amer; Nagah Mohamed Abou Mohamed; Mohamed Ismael Mobasher; Hassan Mamdouh; Sameh Fayek GamalEl Din; Mohammed Said ElSheemy
Journal:  Int Urol Nephrol       Date:  2018-06-28       Impact factor: 2.370

Review 6.  Arginase: an old enzyme with new tricks.

Authors:  Ruth B Caldwell; Haroldo A Toque; S Priya Narayanan; R William Caldwell
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

7.  Binding of α,α-disubstituted amino acids to arginase suggests new avenues for inhibitor design.

Authors:  Monica Ilies; Luigi Di Costanzo; Daniel P Dowling; Katherine J Thorn; David W Christianson
Journal:  J Med Chem       Date:  2011-07-18       Impact factor: 7.446

8.  Molecular targets for diabetes mellitus-associated erectile dysfunction.

Authors:  Elizabeth Yohannes; Jinsook Chang; Moses T Tar; Kelvin P Davies; Mark R Chance
Journal:  Mol Cell Proteomics       Date:  2009-12-10       Impact factor: 5.911

9.  Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism.

Authors:  Jochen Steppan; Sungwoo Ryoo; Karl H Schuleri; Chris Gregg; Rani K Hasan; A Ron White; Lukasz J Bugaj; Mehnaz Khan; Lakshmi Santhanam; Daniel Nyhan; Artin A Shoukas; Joshua M Hare; Dan E Berkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

10.  Arginase inhibition alleviates hypertension in the metabolic syndrome.

Authors:  Hany M El-Bassossy; Rania El-Fawal; Ahmed Fahmy; Malcolm L Watson
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.